🏥CVS Leads $40M Round for H1 Data Provider
Data providers like H1 are still getting funded despite AI hype
TL;DR
Despite the AI craze, traditional data providers like H1 continue to attract investment. CVS led a $40M round for H1, which collects physician data and is forecasted to grow over 40% this year.
CVS Health Ventures has just led a $40 million funding round into H1, a company that sells detailed information about doctors to pharma companies, hospital systems, and health insurers. This move signals that despite the current AI frenzy in tech investment circles, data providers are still valued for their unique business models. For developers working with healthcare data or building tools for medical research, this news highlights that there's still room for traditional data-driven businesses. H1 is projecting over 40% growth this year and turned profitable last year after a $750 million valuation in 2021.
Key Points
CVS Health Ventures led a $40 million funding round for H1, a company selling detailed physician information to pharma and health systems.
H1 is forecasting over 40% growth this year after turning cash flow and EBITDA profitable last year.
The startup was valued at $750 million when it raised $100M from Altimeter Capital in November 2021.
Despite the AI boom, H1 continues to attract investment, highlighting the ongoing value of traditional data-driven businesses.
H1 has grown through acquisitions and complementary business purchases.
Why It Matters
If you're working with healthcare data or building tools for medical research, this news highlights that there's still room for traditional data providers. H1's unique model of selling detailed physician information to pharma companies and health insurers remains valuable despite the current AI investment frenzy.
Frequently Asked Questions
Why does this matter?
If you're working with healthcare data or building tools for medical research, this news highlights that there's still room for traditional data providers. H1's unique model of selling detailed physician information to pharma companies and health insurers remains valuable despite the current AI investment frenzy.
What happened?
Despite the AI craze, traditional data providers like H1 continue to attract investment. CVS led a $40M round for H1, which collects physician data and is forecasted to grow over 40% this year.
Comments
Be the first to comment
Enjoyed this article?
Get it daily. 7am. Free. Reads in 5 minutes.